Serum granulocyte colony‐stimulating factor levels in patients with urinary bladder tumour and various urological malignancies

Mizutani, Youichi; Okada, Yasuhiko; Terachi, Toshiro; Kakehi, Yoshiyuki; Yoshida, Osamu

doi:10.1111/j.1464-410x.1995.tb07782.x

Cited by 27 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…

topoietic cytokines in various malignant diseases, and has generally been considered to reflect the aggressive nature of the tumor and a poor clinical outcome [1] . Herein, we report the first case of prostate cancer producing granulocyte colony-stimulating factor (G-CSF), with an unusual clinical course and immunohistochemical analyses.

Case Report

An 86-year-old man presented with urination difficulties in June 2003.

…”

mentioning

confidence: 99%

Prostate Cancer-Producing Granulocyte Colony-Stimulating Factor

Matsuoka

Arai²,

Okada³

et al. 2009

Urol Int

View full text Add to dashboard Cite

An 86-year-old man with a serum prostate-specific antigen level of 93.33 ng/ml was diagnosed as having cT3aN0M0 prostatic adenocarcinoma of Gleason score 9. Although the serum prostate-specific antigen responded well to combined androgen blockade, the cancer spread and lead to death 6 months after diagnosis. The patient had leukocytosis during the clinical course with no sign of localized infection, especially after manipulation of the prostate. Enzyme immunoassay demonstrated elevated serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor. To our knowledge, this is the first case of prostate cancer with G-CSF production, which was confirmed immunohistochemically.

show abstract

“…

Case Report

An 86-year-old man presented with urination difficulties in June 2003.

…”

mentioning

confidence: 99%

Prostate Cancer-Producing Granulocyte Colony-Stimulating Factor

Matsuoka

Arai²,

Okada³

et al. 2009

Urol Int

View full text Add to dashboard Cite

show abstract

“…In addition, numerous studies have demonstrated that some human bladder cancers may produce G-CSF frequently, presenting leukaemoid reactions (Mizutani et al, 1995). Furthermore, G-CSF production in vitro was demonstrated in another bladder cancer cell line (5637) that is used as a source of G-CSF (Bailly et al, 1995).…”

Section: Discussionmentioning

confidence: 99%

Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder

Tachibana

Miyakawa²,

Uchida³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary Receptors for granulocyte colony-stimulating factor (G-CSFRs) have been confirmed on the cell surfaces of several nonhaematopoietic cell types, including bladder cancer cells. This observation has naturally led to the hypothesis that the expression of G-CSFR on these cells may enhance their growth by G-CSF. In this study, the expression of G-CSFR was determined in both established human bladder cancer cell lines and primary bladder cancers. We studied five different human bladder cancer cell lines (KU-1, KU-7, T-24, NBT-2 and KK) and 26 newly diagnosed bladder tumours. G-CSFR mRNA expressions on cultured cell lines were determined using the reverse transcriptase polymerase chain reaction (RT-PCR) method. Furthermore, the G-CSFR binding experiments on the cultured cell lines were conducted using the Na1251-labelled G-CSF ligand-binding assay method. Moreover, the G-CSFR mRNA expressions on primary bladder tumour specimens were assessed using the in situ RT-PCR method.

show abstract

“…The NSGCT cell lines secreted G-CSF at levels comparable with those measured in the supernatant from some UBT cells (2/4 cell lines 240±23550 pg/ml and 2/4 cell lines <30 pg/ml; Mizutani et al 1995). Both the cell lines producing G-CSF and/or GM-CSF are clones of the multi-potential EC cell line 1777NRp (Bronson et al 1984), which were isolated be D. Bronson following lowdensity passage of 1777NRp (1777NRp Cl-A; Bronson et al 1983Bronson et al 1984;Casper et al paper submitted).…”

Section: Discussioǹ`hmentioning

confidence: 93%

“…In patients with urinary bladder tumour (UBT) an elevated serum G-CSF level has been suggested to be associated with a poor prognosis, the G-CSF being produced by UBT cells (Mizutani et al 1995). IL-6 serum levels have been correlated with the disease status and/or prognosis in patients with renal cell (Blay et al 1992), esophageal (Oka et al 1996), gastric (Wu et al 1996) and ovarian (Berek et al 1991) carcinomas.…”

Section: Introductionmentioning

confidence: 99%

Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines

Dunn

Schmoll

Rie³

et al. 1998

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

Peptide growth factors involved in the regulation of haematopoiesis (HPGF), for example granulocyte-colony-stimulating factor (G-CSF) and granulocyte/macrophage-colony-stimulating factor (GM-CSF), are of clinical importance in the treatment of testicular germ cell tumour (GCT) patients with modern chemotherapy regimens since they ameliorate chemotherapy-induced neutropenia. Aberrant expression of and/or response to HPGF has been reported in several solid tumour types although no data are available on GCT with the exception of those on stem cell factor (SCF). The aims of this pre-clinical study were twofold: (1) to screen a panel of human non-seminomatous (NS)GCT for the production of HPGF and (2) to test the effects of G-CSF or SCF on the growth of NSGCT cell lines in vitro, and on the growth kinetics of two human NSGCT xenograft models. HPGF concentrations in cell culture supernatant from 11 NSGCT cell lines growing under routine culture conditions were measured by enzyme-linked immunosorbent assay. The growth kinetics of cell lines was quantified in vitro using the sulphorhodamine B assay. The growth kinetics of nude mouse NSGCT xenografts was followed by measuring tumour volumes every 2-3 days over days 1-30, following daily subcutaneous injection of nude mice (days 1-14). The cell lines produced G-CSF (1/11 cell lines), GM-CSF (2/11), SCF (2/11), M-CSF (6/11). and interleukin-6 (9/11). Growth stimulation of cell line H12.1 by SCF was observed in vitro, but no statistically significant differences in NSGCT xenograft tumour volume (VT) or relative VT (r VT) in treated groups were observed on days 14 or 29 compared to the control. The change in rVT of H12.1 xenografts treated with G-CSF alone compared to control (rVT/rVT,c) was 0.96 on day 29. The values for rVT/rVT,c for H12.1 xenografts treated with G-CSF in combination with low- or high-dose SCF were, respectively, 1.67 or 1.7 compared to 1.19 for SCF-treated mice. The results are in agreement with clinical data to date where no observations have been reported of stimulation or inhibition of tumours in patients receiving treatment with G-CSF. Before any clinical trials are initiated in GCT patients treated with G-CSF in combination with SCF, further pre-clinical experiments with this tumour type are recommended to investigate this phenomenon further in a greater number of NSGCT cell lines in vitro and in vivo and with a wider range of SCF/G-CSF schedules. The potential relevance of secretion of HPGF in NSGCT cell lines in vitro to the pathobiology of GCT in patients is also a subject of interest for future research.

show abstract

Serum granulocyte colony‐stimulating factor levels in patients with urinary bladder tumour and various urological malignancies

Abstract: These results suggest that elevated serum G-CSF level might be associated with a poor prognosis in patients with UBT and be due to the production of G-CSF by UBT cells.

Cited by 27 publications

References 26 publications

Prostate Cancer-Producing Granulocyte Colony-Stimulating Factor

Prostate Cancer-Producing Granulocyte Colony-Stimulating Factor

Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder

Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines

Contact Info

Product

Resources

About